Clearbridge BioMedics uses its CTChips system to detect, isolate, and retrieve tumour cells from blood samples.
Clearbridge BioMedics, a medical tech company spun off from National University of Singapore, has raised SG$9m ($7.2m) in its series B round.
Vertex Venture, a venture capital [VC] subsidiary of Singapore state-owned investment company Temasek, led the B round, which also included VC firm BioVeda Capital, the government’s co-funding scheme, Spring Seeds Capital, Clearbridge Biomedical Sciences Accelerator, a wholly-owned SG$40m investment subsidiary of Clearbridge Accelerator (CBA), and Lu Yoh Chie, Biosensors International founder and existing shareholder.
Clearbridge BioMedics uses its…
